Artrya Limited · ASX:AYA
Artrya — Shareholder Meeting (November 2024)
16 slides from Artrya's shareholder meeting presentation, Nov 28, 2024
Slide 1: 2024 Chairman and CEO Annual General Meeting Addresses and Presentation
Coronary Artery Disease. We see you. ASX ANNOUNCEMENT For personal use only MARKET RELEASE 28 November 2024 2024 CHAIRMAN AND CEO ANNUAL GENERAL MEETING ADDRESSES AND PRESENTATION Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its paten
Slide 2: Chairman's Address to the Annual General Meeting of Shareholders
Chairman's Address to the Annual General Meeting of Shareholders Welcome to everyone attending our 2024 Annual General Meeting whether that be in person or virtually. It has been another tough year for Artrya but I can say with confidence that we have laid solid foundations For personal use only for
Slide 3: Chairman's Address (continued)
payments from US$175 to US$357 2. Upon FDA clearance of our current 510(k) application, Artrya will be well positioned to access this reimbursement. The payment rate for Automated Plaque Analysis remains at US$9502 per scan, while Fractional Flow Reserve reimbursement has increased from US$997 to US
Slide 4: CEO's Address to the Annual General Meeting of Shareholders
CEO's Address to the Annual General Meeting of Shareholders For personal use only Good morning, and thank you, Bernie, and thank you all for joining us for our Annual General Meeting. My name is Mat Regan, and I am the CEO of Artrya. As Bernie mentioned, my primary focus over the past year has been
Slide 5: CEO's Address (continued)
There are 4.4 million scans per annum and growing at a rate of better than 6% year on year. The Centres of Medicare and Medicaid (CMS) has recently increased the re-imbursements for CCTA to encourage clinicians to use this pathway and we expect further CCTA growth because of this. Slide 7 drills dow
Slide 6: 2024 AGM Artrya Presentation
or personal use only 2024 AGM ARTRYA Presentation 1
Slide 7: Important notice and disclaimer
Important notice and disclaimer IMPORTANT NOTICE or personal use only NOT A DISCLOSURE DOCUMENT FUTURE PERFORMANCE & FORWARD-LOOKING STATEMENTS ELIGIBLE RECEIPIENTS NO RELIANCE ON PRESENTATION • THIS IS NOT AN OFFER OR FINANCIAL PRODUCT ADVICE • • • FINANCIAL AND OTHER DATA NO LIABILITY PAST PERFORM
Slide 8: FY24 Achievements
FY24 Achievements Considerable momentum towards commercialising Salix, primarily in Australia and the US or personal use only ✓ Completed second Q-Sub with the FDA (Aug 24) for Salix Coronary Anatomy ✓ 510(k) FDA application submitted (Sept 24) for Salix Coronary Anatomy ✓ Received FDA registration
Slide 9: Salix Product Roadmap
Salix® Product Roadmap Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. or personal use only Whole Heart Disease Structural Optimised Characterisation Severity Assessment Procedure Detailed Plaque and Dispersion Non-invasive Blood Flow Assessment Structural &
Slide 10: Current State/Competition
Current State/Competition Salix® is system agnostic and simple to deploy, use, and update Onsite or personal use only CCTA Report Review & Prepare Report Manual assessment | No plaque assessment | Limited access to reimbursement Offsite Plaque/FFRCT Report Requires two solutions for CCTA | Absorbs a
Slide 11: Heart disease is a large and growing health challenge, particularly in the US
Heart disease is a large and growing health challenge, particularly in the US or personal use only 12.6 million CCTA scans (RoW)2 US$4.18 billion* Total Addressable Market (US) 6.2% YOY 4.4 Projected growth in Cardiac U.S. patients undergoing CCTA + Plaque Assessment million CCTA CCTA scans to 20281
Slide 12: Salix SaaS Pricing Model – US example
Salix® SaaS Pricing Model – US example Hybrid monthly subscription and fee-per-analysis pricing model or personal use only Benefits: • Provides a single CCTA reporting platform, saving costs • Flexibility on which patients should receive plaque or FFR assessment • Enhances clinician efficiency and p
Slide 13: Drivers of Growth in US Market
Drivers of Growth in US Market Industry tailwinds fuel the high growth outlook, rapidly accelerating growth of CCTA and plaque assessment or personal use only Associations and Reimbursement Key Growth Drivers Plaque Assessment and Treatment • ACC and AHA recommend CCTA as a first-line evaluation for
Slide 14: Salix Demonstration
Salix® Demonstration or personal use only 9
Slide 15: Outlook - six key priorities for CY25
Outlook - six key priorities for CY25 Complete regulatory approvals and enter US market or personal use only 1 Salix Coronary Anatomy: clearance expected first half of CY25 2 Salix Coronary Plaque: clearance targeted for end of mid 2025 3 Salix Coronary Flow: clearance targeted for end of CY25 4 Fir
Slide 16: or personal use only
11 or personal use only